Axsome Therapeutics, Inc. (AXSM) Cash flow
Market cap
$12.1B
P/E ratio
| 2016/12 | 2017/12 | 2018/12 | 2019/12 | 2020/12 | 2021/12 | 2022/12 | 2023/12 | 2024/12 | 2025/12 | |
| Stock-based compensation | 2 | 2 | 2 | 6 | 15 | 21 | 38 | 63 | 85 | 94 |
| Cash from operations | -21,281,304 | -26,471,652 | -30,053,701 | -46,375,059 | -78,456,569 | -108,225,764 | -116,510,798 | -145 | -128 | -93 |
| Capital expenditures | -104,561 | -9,898 | -32,696 | -16,121 | -45,891 | -307,549 | -702,109 | -1 | -0 | -0 |
| Cash from investing | -104,561 | -9,898 | -32,696 | -16,121 | -45,891 | -307,549 | -53,702,109 | -1 | -0 | -0 |
| Proceeds from issuance of term debt, net | 10 | - | - | 20 | 50 | - | - | - | - | - |
| Repayments of term debt | - | - | 3 | 7 | 22 | - | - | - | - | 332 |
| Cash from financing | 10 | 24 | 10 | 252 | 42 | 11 | 285 | 331 | 58 | 101 |
| Free cash flow | ||||||||||
| FCF margin (%) | - | - | - | - | - | - |